文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

泊沙康唑预防重症流感患者侵袭性肺曲霉病(POSA-FLU):一项随机、开放标签、概念验证试验

Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial.
PubMed 文献 · Intensive Care Med · 2021-05-29
一句话结论重症流感患者早期侵袭性肺曲霉病(IAPA)发生率高于预期且病死率高(53%),泊沙康唑预防未能显著降低IAPA发生率。

该随机、开放标签、概念验证试验纳入88例因流感导致呼吸衰竭的ICU成人患者,比较7天静脉泊沙康唑预防与不预防(仅标准治疗)。主要终点为ICU期间IAPA发生率(改良意向治疗人群,即入ICU 48小时内无IAPA者)。泊沙康唑组IAPA发生率为5.4%(2/37),标准治疗组为11.1%(4/36),组间差异5.7%(95% CI -10.8至21.7;p=0.32),未达统计学显著。早期IAPA(入ICU 48小时内诊断)占全部IAPA的71%(15/21),其ICU病死率高达53%。作者认为早期IAPA发生率高于预期使泊沙康唑预防无法得出确定结论,48小时后仍有11%患者发生IAPA,可能需要差异化策略管理ICU中的IAPA。

要点

  • 88例PCR确诊流感、因呼吸衰竭入ICU的成人患者随机接受7天静脉泊沙康唑预防或不预防,改良意向治疗人群中泊沙康唑组IAPA 5.4%(2/37)vs 标准治疗组11.1%(4/36),组间差异5.7%(95% CI -10.8至21.7;p=0.32),未达统计学显著。
  • 全部IAPA中71%(15/21)在入ICU 48小时内诊断,被排除在改良意向治疗人群之外,早期IAPA的ICU病死率高达53%。
  • 入ICU 48小时后仍有11%的患者发生IAPA,作者认为这部分患者可能从预防中获益。
  • 早期IAPA发生率高于预期,使泊沙康唑预防无法得出确定结论;作者认为需要替代管理策略和差异化策略来管理ICU中的IAPA。

适用人群与场景

  • 因流感导致呼吸衰竭入住ICU的成人患者,PCR确诊流感,症状出现10天内且入ICU 48小时内随机分组。
  • 改良意向治疗人群为入ICU 48小时内未诊断IAPA的患者。

处置流程与药物剂量

  • 泊沙康唑组:静脉泊沙康唑预防7天;标准治疗组:不预防,仅标准治疗。

红旗征与不能漏的情况

  • 早期IAPA(入ICU 48小时内诊断)ICU病死率高达53%,尽管及时给予抗真菌治疗。

研究设计与关键结果

  • 随机、开放标签、概念验证试验,88例重症流感患者随机分配至泊沙康唑组或标准治疗组。
  • 全部IAPA发生21例(24%),其中71%(15/21)在入ICU 48小时内诊断。
  • 改良意向治疗人群中,泊沙康唑组IAPA发生率5.4%(2/37)vs 标准治疗组11.1%(4/36),组间差异5.7%(95% CI -10.8至21.7;p=0.32),未达统计学显著。
  • 早期IAPA的ICU病死率为53%。
  • 入ICU 48小时后仍有11%的患者发生IAPA。

证据类型、等级与局限

  • 证据类型:随机、开放标签、概念验证试验(ClinicalTrials.gov,NCT03378479)。
  • 局限:早期IAPA发生率高于预期,使泊沙康唑预防无法得出确定结论。

对床旁实践的改变

  • 作者认为,早期IAPA发生率高于预期且病死率高(53%),尽管及时抗真菌治疗,仍需要替代管理策略。
  • 作者认为,入ICU 48小时后仍有11%的患者发生IAPA,这部分患者可能从预防中获益,可能需要差异化策略来管理ICU中的IAPA。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Influenza-associated pulmonary aspergillosis (IAPA) is a frequent complication in critically ill influenza patients, associated with significant mortality. We investigated whether antifungal prophylaxis reduces the incidence of IAPA.

METHODS: We compared 7 days of intravenous posaconazole (POS) prophylaxis with no prophylaxis (standard-of-care only, SOC) in a randomised, open-label, proof-of-concept trial in patients admitted to an intensive care unit (ICU) with respiratory failure due to influenza (ClinicalTrials.gov, NCT03378479). Adult patients with PCR-confirmed influenza were block randomised (1:1) within 10 days of symptoms onset and 48 h of ICU admission. The primary endpoint was the incidence of IAPA during ICU stay in patients who did not have IAPA within 48 h of ICU admission (modified intention-to-treat (MITT) population).

RESULTS: Eighty-eight critically ill influenza patients were randomly allocated to POS or SOC. IAPA occurred in 21 cases (24%), the majority of which (71%, 15/21) were diagnosed within 48 h of ICU admission, excluding them from the MITT population. The incidence of IAPA was not significantly reduced in the POS arm (5.4%, 2/37) compared with SOC (11.1%, 4/36; between-group difference 5.7%; 95% CI - 10.8 to 21.7; p = 0.32). ICU mortality of early IAPA was high (53%), despite rapid antifungal treatment.

CONCLUSION: The higher than expected incidence of early IAPA precludes any definite conclusion on POS prophylaxis. High mortality of early IAPA, despite timely antifungal therapy, indicates that alternative management strategies are required. After 48 h, still 11% of patients developed IAPA. As these could benefit from prophylaxis, differentiated strategies are likely needed to manage IAPA in the ICU.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Vanderbeke L, Janssen NAF, Bergmans DCJJ, et al. Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Med. 2021. PMID: 34050768. doi:10.1007/s00134-021-06431-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。